ID25449A - Senyawa triazin untuk pengobatan gangguan susunan syaraf pusat (cns) - Google Patents

Senyawa triazin untuk pengobatan gangguan susunan syaraf pusat (cns)

Info

Publication number
ID25449A
ID25449A IDW20001416A ID20001416A ID25449A ID 25449 A ID25449 A ID 25449A ID W20001416 A IDW20001416 A ID W20001416A ID 20001416 A ID20001416 A ID 20001416A ID 25449 A ID25449 A ID 25449A
Authority
ID
Indonesia
Prior art keywords
cns
disturbances
treatment
triazin
compounds
Prior art date
Application number
IDW20001416A
Other languages
English (en)
Inventor
Brian Cox
Mark P Healy
Malcolm S Nobbs
Gita P Shah
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID25449A publication Critical patent/ID25449A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20001416A 1997-12-22 1998-12-18 Senyawa triazin untuk pengobatan gangguan susunan syaraf pusat (cns) ID25449A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726987.2A GB9726987D0 (en) 1997-12-22 1997-12-22 Compounds

Publications (1)

Publication Number Publication Date
ID25449A true ID25449A (id) 2000-10-05

Family

ID=10823992

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001416A ID25449A (id) 1997-12-22 1998-12-18 Senyawa triazin untuk pengobatan gangguan susunan syaraf pusat (cns)

Country Status (34)

Country Link
US (2) US6265405B1 (id)
EP (1) EP1042304A1 (id)
JP (1) JP2001526275A (id)
KR (1) KR20010024800A (id)
CN (1) CN1284951A (id)
AP (1) AP2000001846A0 (id)
AR (1) AR014146A1 (id)
AU (1) AU753874B2 (id)
BR (1) BR9814495A (id)
CA (1) CA2315620A1 (id)
CO (1) CO5011066A1 (id)
EA (1) EA200000561A1 (id)
EE (1) EE200000391A (id)
GB (1) GB9726987D0 (id)
GT (1) GT199800203A (id)
HN (1) HN1998000193A (id)
HR (1) HRP20000419A2 (id)
HU (1) HUP0100611A3 (id)
ID (1) ID25449A (id)
IL (1) IL136867A0 (id)
IS (1) IS5542A (id)
JO (1) JO2065B1 (id)
MA (1) MA26587A1 (id)
NO (1) NO20003211L (id)
NZ (1) NZ505254A (id)
PA (1) PA8465101A1 (id)
PE (1) PE20000063A1 (id)
PL (1) PL341392A1 (id)
SK (1) SK9592000A3 (id)
SV (1) SV1998000151A (id)
TR (1) TR200001970T2 (id)
WO (1) WO1999032462A1 (id)
YU (1) YU39600A (id)
ZA (1) ZA9811725B (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
JP2005514412A (ja) * 2001-12-27 2005-05-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 中枢神経系疾患を処置するために有用なアロイルピロールヘテロアリールおよびメタノール類
DK1524981T3 (da) * 2002-07-29 2009-06-22 Glaxo Group Ltd Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
CA2514574A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10332472A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Tinnitus
US20070276046A1 (en) * 2003-08-25 2007-11-29 Patricia Salvati Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
US20170057943A1 (en) 2015-08-17 2017-03-02 Japan Tobacco Inc. Hydroxytriazine compounds and pharmaceutical use thereof
EP3524605B1 (en) * 2018-02-13 2019-11-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. New efficient process for the preparation of sitagliptin
CN114796146B (zh) * 2022-04-28 2023-03-28 上海奥科达医药科技股份有限公司 一种拉莫三嗪的缓释制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
PL124029B1 (en) * 1979-06-01 1982-12-31 Wellcome Found Process for preparing novel derivatives of 1,2,4-triazine
EP0021120B1 (en) 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
US4311701A (en) 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
CA2137782A1 (en) 1992-06-12 1993-12-23 Meire Nakamura-Craig Therapeutic triazine compounds and use
EP0674627A1 (en) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
GB9305692D0 (en) 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5866597A (en) 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
FR2741879A1 (fr) 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Also Published As

Publication number Publication date
JO2065B1 (en) 2000-05-21
IL136867A0 (en) 2001-06-14
EP1042304A1 (en) 2000-10-11
US6265405B1 (en) 2001-07-24
HUP0100611A2 (hu) 2001-09-28
MA26587A1 (fr) 2004-12-20
GT199800203A (es) 2000-06-14
CA2315620A1 (en) 1999-07-01
AU2414799A (en) 1999-07-12
TR200001970T2 (tr) 2001-01-22
US6465461B1 (en) 2002-10-15
KR20010024800A (ko) 2001-03-26
YU39600A (sh) 2002-11-15
HRP20000419A2 (en) 2000-12-31
NZ505254A (en) 2002-06-28
GB9726987D0 (en) 1998-02-18
WO1999032462A1 (en) 1999-07-01
AU753874B2 (en) 2002-10-31
CN1284951A (zh) 2001-02-21
PA8465101A1 (es) 2000-09-29
SV1998000151A (es) 1999-07-05
PL341392A1 (en) 2001-04-09
AP2000001846A0 (en) 2000-06-30
EA200000561A1 (ru) 2001-04-23
ZA9811725B (en) 2000-06-27
EE200000391A (et) 2002-02-15
NO20003211D0 (no) 2000-06-21
PE20000063A1 (es) 2000-02-16
JP2001526275A (ja) 2001-12-18
CO5011066A1 (es) 2001-02-28
AR014146A1 (es) 2001-02-07
BR9814495A (pt) 2000-10-10
SK9592000A3 (en) 2001-03-12
IS5542A (is) 2000-06-20
NO20003211L (no) 2000-08-21
HUP0100611A3 (en) 2003-03-28
HN1998000193A (es) 2000-04-05

Similar Documents

Publication Publication Date Title
FI963613L (fi) Polyolefiinien stabilointi
PL337738A1 (en) Novel substituted compounds of imidazole
NO980930D0 (no) Arrangement av kontaktpar for kompensering for nær-ende krysstale
NO975775D0 (no) Fremgangsmåte for fremstilling av forbindelser med antifugal aktivitet
ID24638A (id) Senyawa-senyawa anti aritmia bispidina
PL336290A1 (en) Sulphonamides for treating endothelin-involving disorders
IL116998A0 (en) Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
BR9606613A (pt) Pó de alvejamento substancialmente isento de poeira
EE9900273A (et) Luupusnefriidi ravi CD40L-vastaste ühenditega
DE69719815D1 (de) Aminoacyl sulfamiden zur behandlung hyperproliferativer störungen
IL117016A0 (en) Purification of melamine
HUP0100611A3 (en) Triazine compounds for treatment of cns disorders
HUP0003792A3 (en) Novel use of compounds for anti-pruritic activity
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
ID24922A (id) Terapi kombinasi untuk pengobatan aids
HK1028609A (en) Triazine compounds for treatment of cns disorders
NO20006383D0 (no) Fremgangsmåte for behandling
IL117813A0 (en) Use of heterocyclic compounds
IL131765A0 (en) Process for the purification of substituted p-nitrodiphenylethers
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
IL139018A0 (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
AU7521598A (en) Aralkoxy-morphinan derivatives for treatment of cns disorders
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia